Scarica l'app Stockscreener
0.1999
2.46%
0.0048
Dopo l'orario di chiusura:
.20
0.0001
+0.05%
Precedente Chiudi:
$0.1951
Aprire:
$0.199
Volume 24 ore:
1.90M
Relative Volume:
1.05
Capitalizzazione di mercato:
$24.98M
Reddito:
-
Utile/perdita netta:
$-112.46M
Rapporto P/E:
-0.1219
EPS:
-1.64
Flusso di cassa netto:
$-99.89M
1 W Prestazione:
+13.19%
1M Prestazione:
-70.60%
6M Prestazione:
-75.98%
1 anno Prestazione:
-85.08%
Intervallo 1D:
$0.1917
$0.2044
Intervallo di 1 settimana:
$0.1652
$0.2044
Portata 52W:
$0.1311
$1.80
Vor Biopharma Inc Stock (VOR) Company Profile
Nome
Vor Biopharma Inc
Settore
Industria
Telefono
617-655-6580
Indirizzo
100 CAMBRIDGEPARK DRIVE, CAMBRIDGE
Confronta VOR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
0.1999 | 22.07M | 0 | -112.46M | -99.89M | -1.64 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-07-26 | Iniziato | Wedbush | Outperform |
| 2022-04-27 | Iniziato | Goldman | Neutral |
| 2021-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2021-12-03 | Iniziato | Robert W. Baird | Outperform |
| 2021-12-02 | Iniziato | Oppenheimer | Outperform |
| 2021-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-03-25 | Iniziato | B. Riley Securities | Buy |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-03-03 | Iniziato | Evercore ISI | Outperform |
| 2021-03-02 | Iniziato | Goldman | Sell |
| 2021-03-02 | Iniziato | Stifel | Buy |
Mostra tutto
Vor Biopharma Inc Borsa (VOR) Ultime notizie
Vor Biopharma Inc (NASDAQ: VOR) Stock Forecast: Could Pass $6 In A Year - Stocksregister
Vor Biopharma’s SWOT analysis: biotech firm halts programs, explores options - Investing.com
Vor Biopharma Approves Share Increase at Annual Meeting - TipRanks
Vor Biopharma Appoints Robert Ang as CFO - TipRanks
What Did We Note About Insider Trading At Vor Biopharma Inc (NASDAQ: VOR)? - Stocksregister
FMR LLC's Strategic Acquisition of Vor Biopharma Inc Shares - GuruFocus
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Hold” by Analysts - Defense World
Vor Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Vor Biopharma Inc. SEC 10-Q Report - TradingView
Research Analysts’ Recent Ratings Updates for Vor Biopharma (VOR) - Defense World
Vor Biopharma (NYSE:VOR) Cut to “Hold” at Jones Trading - Defense World
JMP Securities Reiterates “Market Perform” Rating for Vor Biopharma (NYSE:VOR) - Defense World
Vor Biopharma’s (VOR) Neutral Rating Reiterated at Wedbush - Defense World
Vor Biopharma (VOR) Downgraded by HC Wainwright & Co. from Buy t - GuruFocus
VorBio (VOR) Downgraded Amid Strategic Review Announcement | VOR Stock News - GuruFocus
Vor Biopharma (VOR) Drops Sharply After Downgrades and Operational Halt - GuruFocus
Stifel cuts Vor Biopharma stock rating amid clinical and financial concerns By Investing.com - Investing.com South Africa
VorBio (VOR) Downgraded as Company Explores Strategic Alternativ - GuruFocus
Stifel cuts Vor Biopharma stock rating amid clinical and financial concerns - Investing.com Canada
Vor Biopharma stock draws downgrades (VOR:NASDAQ) - Seeking Alpha
Layoff Tracker: Shape, Vor Cut Workforces - BioSpace
Vor Biopharma (VOR) Downgraded by JMP Securities | VOR Stock New - GuruFocus
Baird Downgrades Vor Biopharma to Neutral From Outperform - marketscreener.com
This International Paper Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - Benzinga
Vor Biopharma (VOR) Downgraded by HC Wainwright & Co. from Buy to Neutral | VOR Stock News - GuruFocus
Closing Bell Recap: Vor Biopharma Inc (VOR) Ends at 0.16, Reflecting a -70.12 Downturn - DWinneX
VorBio (VOR) Downgraded as Company Shifts Strategy | VOR Stock News - GuruFocus
VorBio (VOR) Downgraded as Company Explores Strategic Alternatives | VOR Stock News - GuruFocus
Stifel Downgrades Vor Biopharma, Inc. (VOR) to Hold - StreetInsider
Baird cuts Vor Biopharma stock rating, slashes target to $0.25 By Investing.com - Investing.com Nigeria
Baird cuts Vor Biopharma stock rating, slashes target to $0.25 - Investing.com
Jones Trading cuts Vor Biopharma stock rating to Hold By Investing.com - Investing.com Nigeria
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga
Jones Trading cuts Vor Biopharma stock rating to Hold - Investing.com
Vor Biopharma stock plummets on operation wind-down - Investing.com Australia
Vor Biopharma stock plummets on operation wind-down By Investing.com - Investing.com Canada
Vor Biopharma Terminates CFO Han Choi - marketscreener.com
Vor Bio Announces Exploration Of Strategic Alternatives To Maximize Shareholder Value - marketscreener.com
Wedbush Downgrades Vor Biopharma to Neutral From Outperform, Adjusts Price Target to $0.40 From $7 - marketscreener.com
Vor Bio (VOR) Downgraded to Hold as Strategic Alternatives Explored | VOR Stock News - GuruFocus
Jones Trading Downgrades Vor Biopharma, Inc. (VOR) to Hold - StreetInsider
Dow Jumps Over 200 Points; US Initial Jobless Claims Fall - Benzinga
Vor Bio (VOR) Explores Strategic Alternatives Amid Operational Wind Down | VOR Stock News - GuruFocus
Vor Biopharma (VOR) Announces Exploration of Strategic Alternatives, Winding Down Operations - StreetInsider
Marshall Wace LLP Sells 79,445 Shares of Vor Biopharma Inc. (NYSE:VOR) - Defense World
Vor Biopharma Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
XTX Topco Ltd Acquires New Position in Vor Biopharma Inc. (NYSE:VOR) - The AM Reporter
Crescent Biopharma Appoints David Lubner to Board of Directors - The Manila Times
PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML) - The Globe and Mail
Vor Biopharma faces Nasdaq delisting over low stock price - Investing.com
Vor Biopharma faces Nasdaq delisting over low stock price By Investing.com - Investing.com India
Vor Biopharma Inc Azioni (VOR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):